ClinicalTrials.gg
Active, not recruitingNCT07730255TAUMUSCLEUpdated Jul 28, 2026

Exercise and Taurine Supplementation on Intramuscular Fat in Older Women With Obesity

An interventional study of Concurrent Exercise Training and Taurine in Obesity (BMI>30), sponsored by University of Sao Paulo. Active, not recruiting at 1 site in Brazil. Open to female participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Obesity by University of Sao Paulo — 5 open to participants now, 11 under way, none of them phase 3. Obesity · University of Sao Paulo.

Planned enrollment
16th of 35
44 · median 40
Started
2026
with 3 others
No phase
30 of 42
5 open now
Primary completion
2026-12
later than 7 of 10 live
Registered
40th of 42
by date

Among the 42 studies in Obesity by University of Sao Paulo, this one is the 16th largest by planned enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2026, is one of 30 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 40th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 42 studies in Obesity by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 60 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Obesity by University of Sao Paulo, or all of them as a file.
02

Study summary

This randomized clinical trial aims to investigate the effects of multicomponent concurrent exercise training associated or not with taurine supplementation on intramuscular fat infiltration, physical performance, transcriptomic profile, and metabolomic profile in older women with obesity. Forty women aged 60 to 75 years with obesity will be randomized into four groups: control, exercise, taurine, and exercise plus taurine. The intervention will last 16 weeks. Outcomes include magnetic resonance imaging, body composition, muscle biopsy, blood biomarkers, functional capacity tests, transcriptomic analysis, and metabolomic analysis.

Read the detailed description

Aging and obesity are associated with important physiological, metabolic, and functional alterations, including increased intramuscular fat infiltration, also known as myosteatosis. Intramuscular fat infiltration is associated with reduced muscle quality, impaired physical performance, metabolic dysfunction, insulin resistance, and increased risk of morbidity and mortality in older adults.

Physical exercise is recognized as an important non-pharmacological strategy to improve muscle function and metabolic health. In addition, taurine supplementation has demonstrated anti-inflammatory and metabolic effects that may contribute to the reduction of intramuscular fat accumulation and improvement of skeletal muscle health.

However, the synergistic effects of concurrent exercise training associated with taurine supplementation on intramuscular fat infiltration and molecular mechanisms involved in older women with obesity are still unclear.

Therefore, this randomized clinical trial aims to investigate the effects of physical exercise associated or not with taurine supplementation on intramuscular fat infiltration, physical performance, body composition, transcriptomic profile, and metabolomic profile in older women with obesity.

Forty women aged 60 to 75 years with obesity (Body mass index - BMI between 30 and 40 kg/m²) will be randomized into four groups:

  • Control group;
  • Exercise group;
  • Taurine supplementation group;
  • Exercise plus taurine supplementation group. The intervention will last 16 weeks. Participants allocated to exercise groups will perform supervised concurrent exercise training three times per week, including resistance and aerobic exercises. Participants allocated to taurine groups will receive 3 grams per day taurine supplementation.

Assessments performed before and after the intervention will include magnetic resonance imaging for intramuscular fat evaluation, body composition by dual-energy X-ray absorptiometry (DXA), muscle biopsy, blood biomarkers, indirect calorimetry, functional capacity tests, muscle strength, transcriptomic analysis, and metabolomic analysis.

This study may contribute to the development of innovative non-pharmacological strategies for obesity, aging, and intramuscular fat infiltration management.

03

Conditions studied

  • Obesity (BMI>30)

Keywords

  • Obesity
  • Taurine
  • Physical Exercise
  • Intramuscular Fat Infiltration
  • Transcriptomics
  • Metabolomics
04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female,
  • 60 and 75 years of age,
  • Body mass lower than 120 kg,
  • Be sedentary (not having engaged in physical exercise for at least 3 months), and
  • between 30 and 40 kg/m².

Exclusion criteria

Exclusion Criteria:

  • alcohol consumption,
  • smoking,
  • infectious and contagious diseases,
  • chronic kidney diseases,
  • undergoing weight loss treatment, and
  • presenting a score ≤13 on cognitive screening using the (MMSE).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    Participants will not receive exercise training or taurine supplementation, only the placebo.

    Other: Placebo

  • Experimental
    Exercise group

    Participants will undergo supervised concurrent exercise training three times per week for 16 weeks and will receive placebo.

    Behavioral: Concurrent Exercise Training · Other: Placebo

  • Experimental
    Taurine supplementation group

    Participants will receive 3 grams per day taurine supplementation for 16 weeks.

    Dietary Supplement: Taurine

  • Experimental
    Exercise plus taurine supplementation group

    Participants will undergo supervised multicomponent concurrent exercise training combined with 3 grams per day taurine supplementation for 16 weeks.

    Behavioral: Concurrent Exercise Training · Dietary Supplement: Taurine

Interventions

  • BehavioralConcurrent Exercise Training

    Participants will perform supervised concurrent exercise training three times per week for 16 weeks. Exercise sessions will include warm-up, resistance exercises, aerobic training, and stretching exercises, according to American College of Sports Medicine (ACSM) recommendations for older adults.

  • Dietary supplementTaurine

    Participants will receive 3 grams per day taurine supplementation administered orally in capsules for 16 weeks.

  • OtherPlacebo

    Participants will receive placebo capsules identical in appearance to taurine capsules.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Intramuscular Fat Fraction Assessed by Magnetic Resonance Imaging (Dixon Technique)

    Intramuscular fat fraction assessed by magnetic resonance imaging (MRI) using the Dixon technique, reported as percentage (%) of fat within the muscle tissue. Change is calculated from baseline to Week 16.

    Time frame: Baseline and 16 weeks

  2. Change from baseline in skeletal muscle transcriptomic profile

    Skeletal muscle biopsy samples will be analyzed using RNA sequencing to characterize changes in the skeletal muscle transcriptomic profile following the intervention.

    Time frame: Baseline and 16 weeks

  3. Change from baseline in plasma metabolomic profile

    Plasma samples will be analyzed using untargeted metabolomic analysis to evaluate changes in the plasma metabolomic profile after 16 weeks of intervention.

    Time frame: 16 weeks

  4. Change from baseline in plasma taurine concentration

    Plasma taurine concentration will be measured before and after the 16-week intervention.

    Time frame: Baseline and 16 weeks

Secondary outcomes

  1. Change from baseline in Timed Up and Go test time

    Functional mobility will be assessed using the Timed Up and Go test.

    Time frame: Baseline and 16 weeks

  2. Change from baseline in handgrip strength

    Handgrip strength will be assessed using a hand dynamometer.

    Time frame: Baseline and 16 weeks

  3. Change from baseline in chair stand test performance

    Lower-body functional performance will be assessed using the Chair Stand Test.

    Time frame: Baseline and 16 weeks

  4. Change from baseline in forearm flexion test performance

    Upper-body muscular endurance will be assessed using the Forearm Flexion Test.

    Time frame: Baseline and 16 weeks

  5. Change from baseline in isokinetic knee extensor peak torque

    Peak torque of the knee extensor muscles will be measured using an isokinetic dynamometer.

    Time frame: Baseline and 16 weeks

  6. Change from baseline in fat-free mass

    Fat-free mass will be assessed by dual-energy X-ray absorptiometry.

    Time frame: Baseline and 16 weeks

  7. Change from baseline in fat mass

    Fat mass will be assessed by dual-energy X-ray absorptiometry.

    Time frame: Baseline and 16 weeks

  8. Change from baseline in fasting blood glucose concentration

    Fasting blood glucose concentration will be measured using blood samples collected after an overnight fast.

    Time frame: Baseline and 16 weeks

  9. Change from baseline in fasting insulin concentration

    Fasting insulin concentration will be measured using blood samples collected after an overnight fast.

    Time frame: Baseline and 16 weeks

  10. Change from baseline in total cholesterol concentration

    Total cholesterol concentration will be measured using fasting blood samples.

    Time frame: Baseline and 16 weeks

  11. Change from baseline in high-density lipoprotein cholesterol concentration

    High-density lipoprotein cholesterol concentration will be measured using fasting blood samples.

    Time frame: Baseline and 16 weeks

  12. Change from baseline in low-density lipoprotein cholesterol concentration

    Low-density lipoprotein cholesterol concentration will be measured using fasting blood samples.

    Time frame: Baseline and 16 weeks

  13. Change from baseline in triglyceride concentration

    Triglyceride concentration will be measured using fasting blood samples.

    Time frame: Baseline and 16 weeks

  14. Change from baseline in resting metabolic rate

    Resting metabolic will be assessed by indirect calorimetry after an overnight fast.

    Time frame: Baseline and 16 weeks

07

Study locations

1 site
  • Escola de Educação Física e Esporte de Ribeirão Preto, Ribeirão Preto, São Paulo.
    Ribeirão Preto, São Paulo 14040-900, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 7 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jul 28, 2026
StartActual
May 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730255
Responsible party
Ellen Cristini de Freitas (Principal Investigator, University of Sao Paulo) — Principal investigator
First posted
Jul 28, 2026
Start date
May 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Ellen C de Freitas, Doctor
principal investigator · University of Sao Paulo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taurine

Start the discussion